SPD 2026 highlighted advances in pediatric dermatology spanning textured hair care, vitiligo, vascular anomalies, mental health, genetics, and collaborative care.
|Videos|March 26, 2022
Updates in HS and PRP
Author(s)Linda Stocum, Associate Editor
In this video interview, we sit down with both Jennifer Lin Hsiao, MD, FAAD, and Scott Worswick, MD, FAAD, to talk in detail about their presentation, "Hidradenitis Suppurativa and Pityriasis Rubra Pilaris: Updates on Treatments for Two Conditions that are Difficult to Manage."
Advertisement
Advertisement
Related to this article
Two-year oral IL-23 data, GLP-1 biomarker findings, and a nonsurgical option for superficial basal cell carcinoma headline the sessions covered in Las Vegas.
A retrospective claims analysis of 2897 matched pairs found hazard ratios of 0.48 to 0.67 for new atopic disease with dupilumab vs systemic corticosteroids in children.
Falk G. Bechara, MD, discusses long-term tunnel control, structural damage, and the evolving role of biologics and surgery in HS care.
Elevate-Derm Summer 2026 faculty share practical lessons on hair loss exams, PIH, geriatric dermatology, and managing cholesterol rises on JAK inhibitors.
The 3rd annual meeting in Atlanta gives dermatology NPs and PAs 4 case-based breakout sessions and a general education session in a focused, small-group setting.
Lutikizumab significantly improved HiSCR75 response, pain, and disease flares in adults and adolescents with moderate to severe HS.
The joint AAD-HSF guideline issues 37 recommendations, including strong support for adalimumab, bimekizumab, infliximab, and secukinumab.
Advertisement
Advertisement
Trending on Dermatology Times
1
FDA Approves Tildrakizumab for Active Psoriatic Arthritis
2
The Scariest Skin Care Trends Haunting Patients This Halloween
3
Improving Early Identification and Escalation of HS
4
October Social Media Mythbusters: 3 Viral Beauty Claims, Debunked
5